Preclinical investigations have indicated that IMiD therapy improves T cell co-stimulation and growth by increasing pro-inflammatory cytokines like IL-2, TNF-α, and IFN-γ, and lowering anti-inflammatory cytokines like TGF-β and IL-10 in CLL [140]. Here, IL2 is linked to B-cell chronic lymphocytic leukemia.